Evaluation of soy phytoestrogens for the treatment of hot flashes in XXXX survivors: A North Central Cancer Treatment Group Trial.

@entity172 @entity1 @entity137 @entity0 @entity1420 @entity1460
PURPOSE: Hot flashes represent a significant clinical problem for some @entity0 survivors. Safe, effective treatment is needed for this prominent clinical problem. Although it has been shown that @entity172 or @entity1420 replacement therapy can alleviate this problem, there are continued safety concerns regarding the use of hormonal therapies in these @entity1 . Based on anecdotal information, we hypothesized that soy-derived phytoestrogens, weak @entity172 -like substances in the @entity1460 that demonstrate @entity172 agonist and/or antagonist effects when they bind to @entity172 receptors, could alleviate hot flashes. This current trial was designed to investigate this hypothesis. @entity1 AND METHODS: This double-blind clinical trial involved @entity0 survivors with substantial hot flashes. After randomization, @entity1 underwent a 1-week baseline period with no therapy. This was followed by 4 weeks of either soy tablets or placebo. The @entity1 then crossed over to the opposite arm in a double-blind manner for the last 4 weeks. @entity1 completed a daily questionnaire documenting hot flash frequency, intensity, and perceived side effects. RESULTS: Of the 177 @entity1 who were randomized and started the study substance, 155 (88%) provided useable data over the first 5 weeks; 149 provided usable data over the entire 9 weeks. There was no suggestion that the soy product was more effective in reducing hot flashes than the placebo. At study completion, @entity1 preferred the soy product 33% of the time, the placebo 37% of the time, and neither substance 31% of the time. No @entity137 was observed. CONCLUSION: The soy product did not alleviate hot flashes in @entity0 survivors.
